Literature DB >> 28785939

Small Colony Variants of Pseudomonas aeruginosa Display Heterogeneity in Inhibiting Aspergillus fumigatus Biofilm.

Rajesh Anand1,2,3, Richard B Moss4, Gabriele Sass5,6, Niaz Banaei7, Karl V Clemons5,6, Marife Martinez5, David A Stevens5,6.   

Abstract

Pseudomonas aeruginosa and Aspergillus fumigatus are major microbes in cystic fibrosis (CF). We reported non-mucoid P. aeruginosa isolates more inhibitory to A. fumigatus than mucoid ones. Another CF P. aeruginosa phenotype, small colony variants (SCVs), is an unknown factor in intermicrobial competition with A. fumigatus. Clinical SCV isolates and reference CF non-mucoid isolate (Pa10, producing normal-sized colonies) were compared. Live cells of P. aeruginosa or filtrates from P. aeruginosa planktonic or biofilm cultures were co-incubated with A. fumigatus growing under conditions allowing biofilm formation or with preformed biofilm. Metabolic activity of A. fumigatus biofilm was then measured. When necessary, assays were done after adjustment for growth differences by adding fresh medium to the planktonic culture filtrate. Pyoverdine determinations were performed spectrophotometrically on the planktonic culture filtrates. In all experimental conditions (live cells and planktonic or biofilm culture filtrates of P. aeruginosa versus A. fumigatus biofilm formation or preformed biofilm), three SCV isolates were less inhibitory than Pa10, two equal or more inhibitory. Adjusting planktonic culture filtrates for growth differences showed SCV inhibition differences variably related to growth or deficient inhibitor production. Studies suggested the principal P. aeruginosa inhibitor to be pyoverdine. SCV isolates appear heterogeneous in their capacity to inhibit A. fumigatus biofilm. SCV isolates can be important in the CF microbiome, because they are capable of intermicrobial inhibition.

Entities:  

Keywords:  Aspergillus; Cystic fibrosis; Intermicrobial inhibition; Pseudomonas; Small colony variants

Mesh:

Substances:

Year:  2017        PMID: 28785939     DOI: 10.1007/s11046-017-0186-9

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  35 in total

Review 1.  Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis.

Authors:  Thomas J Evans
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

2.  Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S Häussler; B Tümmler; H Weissbrodt; M Rohde; I Steinmetz
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

3.  The influence of respiratory bacteria and their biochemical fractions on Aspergillus fumigatus.

Authors:  W Blyth; A Forey
Journal:  Sabouraudia       Date:  1971-11

4.  Interactions between some aural aspergillus species and bacteria.

Authors:  A Mangan
Journal:  J Gen Microbiol       Date:  1969-10

Review 5.  Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective.

Authors:  Anders Folkesson; Lars Jelsbak; Lei Yang; Helle Krogh Johansen; Oana Ciofu; Niels Høiby; Søren Molin
Journal:  Nat Rev Microbiol       Date:  2012-11-13       Impact factor: 60.633

Review 6.  Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung.

Authors:  Michael Hogardt; Jürgen Heesemann
Journal:  Int J Med Microbiol       Date:  2010-10-12       Impact factor: 3.473

7.  Aspergillus bronchitis in cystic fibrosis.

Authors:  David Shoseyov; Keith G Brownlee; Steven P Conway; Eitan Kerem
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

8.  Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis.

Authors:  D W Denning; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Dirhamnolipids secreted from Pseudomonas aeruginosa modify anjpegungal susceptibility of Aspergillus fumigatus by inhibiting β1,3 glucan synthase activity.

Authors:  Benoit Briard; Vero Rasoldier; Perrine Bomme; Noureddine ElAouad; Catherine Guerreiro; Pierre Chassagne; Laetitia Muszkieta; Jean-Paul Latgé; Laurence Mulard; Anne Beauvais
Journal:  ISME J       Date:  2017-03-24       Impact factor: 10.302

10.  Effect of acute predation with bacteriophage on intermicrobial aggression by Pseudomonas aeruginosa.

Authors:  Patrick R Secor; Gabriele Sass; Hasan Nazik; David A Stevens
Journal:  PLoS One       Date:  2017-06-16       Impact factor: 3.240

View more
  6 in total

1.  Fungal Respiratory Infections in Cystic Fibrosis (CF): Recent Progress and Future Research Agenda.

Authors:  Jean-Philippe Bouchara; Françoise Symoens; Carsten Schwarz; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2018-02       Impact factor: 2.574

2.  Co-Operative Biofilm Interactions between Aspergillus fumigatus and Pseudomonas aeruginosa through Secreted Galactosaminogalactan Exopolysaccharide.

Authors:  Hanna Ostapska; François Le Mauff; Fabrice N Gravelat; Brendan D Snarr; Natalie C Bamford; Jaime C Van Loon; Geoffrey McKay; Dao Nguyen; P Lynne Howell; Donald C Sheppard
Journal:  J Fungi (Basel)       Date:  2022-03-24

Review 3.  Factoring in the Complexity of the Cystic Fibrosis Lung to Understand Aspergillus fumigatus and Pseudomonas aeruginosa Interactions.

Authors:  Emily Beswick; Jorge Amich; Sara Gago
Journal:  Pathogens       Date:  2020-08-06

4.  Interaction between Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis.

Authors:  Jingming Zhao; Wencheng Yu
Journal:  PeerJ       Date:  2018-11-09       Impact factor: 2.984

5.  Aspergillus Is Inhibited by Pseudomonas aeruginosa Volatiles.

Authors:  Hasan Nazik; Gabriele Sass; Eric Déziel; David A Stevens
Journal:  J Fungi (Basel)       Date:  2020-07-25

6.  Perspectives of Phage Therapy in Non-bacterial Infections.

Authors:  Andrzej Górski; Paul L Bollyky; Maciej Przybylski; Jan Borysowski; Ryszard Międzybrodzki; Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska
Journal:  Front Microbiol       Date:  2019-01-09       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.